Loading...
XSTOBIOVIC B
Market cap14mUSD
Dec 23, Last price  
1.73SEK
1D
-0.57%
1Q
-32.68%
IPO
-86.48%
Name

Biovica International AB

Chart & Performance

D1W1MN
XSTO:BIOVIC B chart
P/E
—
P/S
21.44
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
25.33%
Rev. gr., 5y
19.39%
Revenues
7m
+115.43%
4,045,026459,0002,432,000632,0002,723,0003,005,0001,671,0002,077,0002,045,0003,384,0007,290,000
Net income
-125m
L+12.97%
-5,371,659-7,043,000-5,031,000-14,857,000-18,064,000-21,556,000-30,318,000-39,483,000-60,003,000-110,492,000-124,823,000
CFO
-115m
L+21.06%
0922,000-9,385,000-11,090,000-14,882,000-17,966,000-24,780,000-34,409,000-52,126,000-94,640,000-114,575,000
Earnings
Mar 13, 2025

Profile

Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
URL
https://biovica.com/
IPO date
Mar 29, 2017
Employees
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑042023‑042022‑042021‑042020‑042019‑042018‑042017‑042016‑042015‑04
Income
Revenues
7,290
115.43%
3,384
65.48%
2,045
-1.54%
Cost of revenue
5,501
4,117
10,381
Unusual Expense (Income)
NOPBT
1,789
(733)
(8,336)
NOPBT Margin
24.54%
Operating Taxes
687
(187)
12
Tax Rate
38.40%
NOPAT
1,102
(546)
(8,348)
Net income
(124,823)
12.97%
(110,492)
84.14%
(60,003)
51.97%
Dividends
Dividend yield
Proceeds from repurchase of equity
99,121
150,090
1,201
BB yield
-106.73%
-55.96%
-0.12%
Debt
Debt current
3,532
3,149
4,464
Long-term debt
12,124
17,757
22,030
Deferred revenue
(2,710)
(2,666)
Other long-term liabilities
999
2,710
2,666
Net debt
(64,200)
(93,421)
(63,296)
Cash flow
Cash from operating activities
(114,575)
(94,640)
(52,126)
CAPEX
(146)
(2,779)
(3,398)
Cash from investing activities
(585)
(2,779)
(3,398)
Cash from financing activities
79,502
122,009
(136)
FCF
4,198
1,882
(18,971)
Balance
Cash
79,407
114,327
89,790
Long term investments
449
Excess cash
79,492
114,158
89,688
Stockholders' equity
(447,687)
(186,784)
(91,986)
Invested Capital
552,156
335,048
229,237
ROIC
0.25%
ROCE
1.68%
EV
Common stock shares outstanding
58,408
37,046
30,587
Price
1.59
-78.04%
7.24
-77.23%
31.80
-21.87%
Market cap
92,869
-65.37%
268,213
-72.43%
972,679
-21.77%
EV
28,669
313,310
1,033,356
EBITDA
6,130
7,481
(1,897)
EV/EBITDA
4.68
41.88
Interest
289
10
79
Interest/NOPBT
16.15%